<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLUDROCORTISONE ACETATE<img border="0" src="../images/pr.gif"/></span><br/>(floo-droe-kor'ti-sone)<br/><span class="topboxtradename">Florinef Acetate<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">adrenal corticosteroid</span>; <span class="classification">mineralocorticoid</span>; <span class="classification">antiinflammatory agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.1 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Long-acting synthetic steroid with potent mineralocorticoid and moderate glucocorticoid activity. Small doses produce marked
         sodium retention, increased urinary potassium excretion, and elevated BP.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Synthetic corticosteroid replacement product for adrenocortical insufficiency.</p>
<h1><a name="uses">Uses</a></h1>
<p>Partial replacement therapy for adrenocortical insufficiency and for treatment of salt-losing forms of congenital adrenogenital
         syndrome.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>To increase systolic and diastolic blood pressure in patients with severe hypotension secondary to diabetes mellitus or to
         levodopa therapy.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to glucocorticoids, idiopathic thrombocytopenic purpura, psychoses, acute glomerulonephritis, viral or bacterial
         diseases of skin, infections not controlled by antibiotics, active or latent amebiasis, hypercorticism (Cushing's syndrome),
         smallpox vaccination or other immunologic procedures. Topical steroids are contraindicated in presence of varicella, vaccinia,
         on surfaces with compromised circulation, and in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Children; diabetes mellitus; chronic, active hepatitis positive for hepatitis B surface antigen; hyperlipidemia; cirrhosis;
         stromal herpes simplex; glaucoma, tuberculosis of eye; osteoporosis; convulsive disorders; hypothyroidism; diverticulitis;
         nonspecific ulcerative colitis; fresh intestinal anastomoses; active or latent peptic ulcer; gastritis; esophagitis; thromboembolic
         disorders; CHF; metastatic carcinoma; hypertension; renal insufficiency; history of allergies; active or arrested tuberculosis;
         systemic fungal infection; myasthenia gravis. Safety in pregnancy (category C) or lactation is not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adrenocortical Insufficiency</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.1 mg/d, may range from 0.1 mg 3 times/wk to 0.2 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.050.1 mg/d<br/><br/><span class="indicationtitle">Salt-Losing Adrenogenital Syndrome</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 0.10.2 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 0.050.1 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>
            				Note: Concomitant oral cortisone or hydrocortisone therapy may be advisable to provide substitute therapy approximating normal adrenal
            activity.
            			
         </li>
<li>Store in airtight containers at 15°30° C (59°86° F). Protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Vertigo, headache, nystagmus, increased intracranial pressure with papilledema (usually after discontinuation of medication),
      mental disturbances, aggravation of preexisting psychiatric conditions, insomnia, ataxia (rare). <span class="typehead">CV:</span> CHF, hypertension, <span class="speceff-life">thromboembolism</span> (rare), tachycardia. <span class="typehead">Endocrine:</span> Suppressed linear growth in children, decreased glucose tolerance; hyperglycemia, manifestations of latent diabetes mellitus;
      hypocorticism; amenorrhea and other menstrual difficulties. <span class="typehead">Special Senses:</span> Posterior subcapsular cataracts (especially in children), glaucoma, exophthalmos, increased intraocular pressure with optic
      nerve damage, perforation of the globe. <span class="typehead">Metabolic:</span> Hypocalcemia; <span class="speceff-common">sodium and fluid retention;</span> hypokalemia and hypokalemic alkalosis, negative nitrogen balance, decreased serum concentration of vitamins A and C. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> increased appetite, ulcerative esophagitis, pancreatitis, abdominal distension, peptic ulcer with perforation and hemorrhage,
      melena. <span class="typehead">Hematologic:</span> Thrombocytopenia. <span class="typehead">Musculoskeletal:</span> (long-term use) Osteoporosis, compression fractures, muscle wasting and weakness, tendon rupture, aseptic necrosis of femoral
      and humeral heads. <span class="typehead">Skin:</span> Skin thinning and atrophy, <span class="speceff-common">acne, impaired wound healing;</span> petechiae, ecchymosis, easy bruising; suppression of skin test reaction; hypopigmentation or hyperpigmentation, hirsutism,
      acneiform eruptions, subcutaneous fat atrophy; allergic dermatitis, urticaria, angioneurotic edema, increased sweating. <span class="typehead">Body as a Whole:</span>
<span class="speceff-life">Anaphylactoid reactions</span> (rare), <span class="speceff-life">aggravation or masking of infections</span>; malaise, weight gain, obesity. <span class="typehead">Urogenital:</span> Increased or decreased motility and number of sperm. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> The antidiabetic effects of <b>insulin</b> and <span class="classification">sulfonylureas</span> may be diminished; <b>amphotericin B,</b>
<span class="classification">diuretics</span> may increase <b>potassium</b> loss; <b>warfarin</b> may decrease prothrombin time; <b>indomethacin,</b>
<b>ibuprofen</b> can potentiate the pressor effect of fludrocortisone; <span class="classification">anabolic steroids</span> increase risk of edema and acne; <b>rifampin</b> may increase the hepatic metabolism of fludrocortisone. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 1.7 h. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Half-Life:</span> 3.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor weight and I&amp;O ratio to observe onset of fluid accumulation, especially if patient is on unrestricted salt intake
            and without potassium supplement. Report weight gain of 2 kg (5 lb)/wk.
         </li>
<li>Monitor and record BP daily. If hypertension develops as a consequence of therapy, report to physician. Usually, the dose
            will be reduced to 0.05 mg/d.
         </li>
<li>Check BP q46h and weight at least every other day during periods of dosage adjustment.</li>
<li>Lab tests: Periodic serum electrolytes and ABGs during prolonged therapy.</li>
<li>Monitor for S&amp;S of hypokalemia and hyperkalemic metabolic alkalosis (see Appendix F).</li>
<li>Monitor for signs of overdosage (hypercorticism): psychosis, excess weight gain, edema, congestive heart failure, ravenous
            appetite, severe insomnia, and increase in BP.
         </li>
<li>
            							Note: Signs of insufficient dosage (hypocorticism) are loss of weight and appetite, nausea, vomiting, diarrhea, muscular weakness,
            increased fatigue, and hypotension.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report signs of hypokalemia (see Appendix F).</li>
<li>Be aware of signs of potassium depletion associated with high sodium intake: Muscle weakness, paresthesias, circumoral numbness;
            fatigue, anorexia, nausea, mental depression, polyuria, delirium, diminished reflexes, arrhythmias, cardiac failure, ileus,
            ECG changes.
         </li>
<li>Advise patient to eat foods with high potassium content.</li>
<li>Signs of edema should be reported immediately. Sodium intake may or may not require regulation, depending on individual needs
            and clinical situation.
         </li>
<li>Weigh daily under standard conditions and report steady weight gain.</li>
<li>Report intercurrent infection, trauma, or unexpected stress of any kind promptly when taking maintenance therapy.</li>
<li>Carry medical identification at all times. It needs to indicate medical diagnosis, medication(s), physician's name, address,
            and telephone number.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>